Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

ClinicalTrials.gov ID: NCT02547922

Public ClinicalTrials.gov record NCT02547922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).

Study identification

NCT ID: NCT02547922
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 147 participants

Conditions and interventions

Conditions

Lupus Nephritis

Interventions

Anifrolumab Biological
Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 3, 2015
Primary completion: Nov 25, 2019
Completion: Jan 17, 2021
Last update posted: Nov 23, 2021

2015 – 2021

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research Site	Glendale	Arizona	85306	—
Research Site	Phoenix	Arizona	85032	—
Research Site	La Jolla	California	92037-0706	—
Research Site	Los Angeles	California	90095-1670	—
Research Site	Thousand Oaks	California	91360	—
Research Site	Aurora	Colorado	80045	—
Research Site	DeBary	Florida	32713	—
Research Site	Boston	Massachusetts	02118	—
Research Site	Newark	New Jersey	07103-2499	—
Research Site	Great Neck	New York	11021	—
Research Site	New Hyde Park	New York	11042	—
Research Site	New York	New York	10016	—
Research Site	New York	New York	10029	—
Research Site	The Bronx	New York	10457	—
Research Site	Columbus	Ohio	43210	—
Research Site	Oklahoma City	Oklahoma	73104	—
Research Site	Memphis	Tennessee	38119	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02547922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 23, 2021 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02547922 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →